Janssen: CHMP Recommends Janssen's Rybrevant + Lazcluze For EGFR-mutated Advanced Non-small Cell Lung Cancer
NEW BRUNSWICK (dpa-AFX) - Janssen-Cilag International NV, a Johnson & Johnson company, Friday announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Age...
Read full article »
Janssen is a New Jersey-based pharmaceutical firm that researches and develops medicinal products for the treatment of oncology, cardiovascular and immunology.
Read more